Uropathogenic escherichia coli mediated urinary tract infection

Current Drug Targets

Volumn 13, Issue 11, 2012, Pages 1386-1399

  Totsika, Makrina ^a   Moriel, Danilo Gomes ^a   Idris, Adi ^a   Rogers, Benjamin A ^a,b   Wurpel, Daniël J ^a   Phan, Minh Duy ^a   Paterson, David L ^a,b   Schembri, Mark A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antibiotic resistance; Uropathogenic Escherichia coli; Vaccine; Virulence

Indexed keywords

ADHESIN; AEROBACTIN; AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFALEXIN; CIPROFLOXACIN; COTRIMOXAZOLE; DORIPENEM; ENTEROCHELIN; ERTAPENEM; ESCHERICHIA COLI ENDOTOXIN; ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI PROTEIN; ESCHERICHIA COLI VACCINE; FIMBRIA PROTEIN; FOSFOMYCIN; IMIPENEM; IRON BINDING PROTEIN; MEROPENEM; NITROFURANTOIN; O ANTIGEN; PIVMECILLINAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALMOCHELIN; SOLCO UROVAC; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRULENCE FACTOR; YERSINIABACTIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CELL INVASION; CLONAL SPECIES; DRUG EFFICACY; ESCHERICHIA COLI INFECTION; FIMBRIA; HEALTH CARE COST; HOSPITALIZATION; HOST CELL; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; REVIEW; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; UROTHELIUM; VACCINATION;

ANTI-BACTERIAL AGENTS; BACTERIAL VACCINES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; URINARY TRACT INFECTIONS; VIRULENCE;

EID: 84866915086     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530206     Document Type: Review

References (209)

1. Foxman B, Manning SD, Tallman P, et al. Uropathogenic Escherichia coli are more likely than commensal E. coli to be shared between heterosexual sex partners. Am J Epidemiol 2002; 156(12): 1133-40.
2. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol 2004; 2(2): 123-40.
3. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001; 183 Suppl 1: S1-4.
4. Bidet P, Mahjoub-Messai F, Blanco J, et al. Combined multilocus sequence typing and O serogrouping distinguishes Escherichia coli subtypes associated with infant urosepsis and/or meningitis. J Infect Dis 2007; 196(2): 297-303.
5. Klemm P, Schembri MA. Bacterial adhesins: function and structure. Int J Med Microbiol 2000; 290(1): 27-35.
6. Wiles TJ, Kulesus RR, Mulvey MA. Origins and virulence mechanisms of uropathogenic Escherichia coli. Exp Mol Pathol 2008; 85(1): 11-9.
7. Oelschlaeger TA, Dobrindt U, Hacker J. Virulence factors of uropathogens. Curr Opin Urol 2002; 12(1): 33-8.
8. Wright KJ, Seed PC, Hultgren SJ. Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization. Infect Immun 2005; 73(11): 7657-68.
9. Lane MC, Alteri CJ, Smith SN, Mobley HL. Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci USA 2007; 104(42): 16669-74.
10. Lane MC, Lockatell V, Monterosso G, et al. Role of Motility in the Colonization of Uropathogenic Escherichia coli in the Urinary Tract. Infect Immun 2005; 73(11): 7644-56.
11. Lane MC, Lockatell V, Monterosso G, et al. Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract. Infect Immun 2005; 73(11): 7644-56.
12. Sauer FG, Remaut H, Hultgren SJ, Waksman G. Fiber assembly by the chaperone-usher pathway. Biochim Biophys Acta 2004; 1694(1-3): 259-67.
13. Bergsten G, Samuelsson M, Wullt B, Leijonhufvud I, Fischer H, Svanborg C. PapG-dependent adherence breaks mucosal inertia and triggers the innate host response. J Infect Dis 2004; 189(9): 1734-42.
14. Roberts JA, Kaack MB, Baskin G, et al. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. J Urol 2004; 171(4): 1682-5.
15. Roberts JA, Marklund BI, Ilver D, et al. The Gal(alpha 1-4)Galspecific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract. Proc Natl Acad Sci USA 1994; 91(25): 11889-93.
16. Hedges SR, Agace WW, Svanborg C. Epithelial cytokine responses and mucosal cytokine networks. Trends Microbiol 1995; 3(7): 266-70.
17. Connell H, Agace W, Klemm P, Schembri M, Marild S, Svanborg C. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci USA 1996; 93(18): 9827-32.
18. Mulvey MA, Lopez-Boado YS, Wilson CL, et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 1998; 282(5393): 1494-7.
19. Klemm P, Schembri MA. Type 1 Fimbriae, Curli, and Antigen 43: Adhesion, Colonization, and Biofilm Formation. In: R Curtiss III EcoSal-Escherichia coli and Salmonella: (Eds.) Cellular and Molecular Biology [Online] http://wwwecosalorg ASM Press, (Washington, DC).
20. Wu XR, Sun TT, Medina JJ. In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc Natl Acad Sci USA 1996; 93(18): 9630-5.
21. Kuehn MJ, Heuser J, Normark S, Hultgren SJ. Ppili in uropathogenic E. coli are composite fibres with distinct fibrillar adhesive tips. Nature 1992; 356(6366): 252-5.
22. Jones CH, Pinkner JS, Roth R, et al. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc Natl Acad Sci USA 1995; 92(6): 2081-5.
23. Choudhury D, Thompson A, Stojanoff V, et al. X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science 1999; 285(5430): 1061-6.
24. Welch RA, Burland V, Plunkett G 3rd, et al. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc Natl Acad Sci USA 2002; 99(26): 17020-4.
25. van Die I, Kramer C, Hacker J, Bergmans H, Jongen W, Hoekstra W. Nucleotide sequence of the genes coding for minor fimbrial subunits of the F1C fimbriae of Escherichia coli. Res Microbiol 1991; 142(6): 653-8.
26. Klemm P, Jorgensen BJ, Kreft B, Christiansen G. The export systems of type 1 and F1C fimbriae are interchangeable but work in parental pairs. J Bacteriol 1995; 177(3): 621-7.
27. Klemm P, Christiansen G, Kreft B, Marre R, Bergmans H. Reciprocal exchange of minor components of type 1 and F1C fimbriae results in hybrid organelles with changed receptor specificities. J Bacteriol 1994; 176(8): 2227-34.
28. Bäckhed F, Alsen B, Roche N, et al. Identification of target tissue glycosphingolipid receptors for uropathogenic, F1C-fimbriated Escherichia coli and its role in mucosal inflammation. J Biol Chem 2002; 277(20): 18198-205.
29. Khan AS, Kniep B, Oelschlaeger TA, Van Die I, Korhonen T, Hacker J. Receptor structure for F1C fimbriae of uropathogenic Escherichia coli. Infect Immun 2000; 68(6): 3541-7.
30. Korhonen TK, Vaisanen-Rhen V, Rhen M, Pere A, Parkkinen J, Finne J. Escherichia coli fimbriae recognizing sialyl galactosides. J Bacteriol 1984; 159(2): 762-6.
31. Servin AL. Pathogenesis of Afa/Dr diffusely adhering Escherichia coli. Clin Microbiol Rev 2005; 18(2): 264-92.
32. Ulett GC, Mabbett AN, Fung KC, Webb RI, Schembri MA. The role of F9 fimbriae of uropathogenic Escherichia coli in biofilm formation. Microbiology 2007; 153(Pt 7): 2321-31.
33. Ong CL, Ulett GC, Mabbett AN, et al. Identification of type 3 fimbriae in uropathogenic Escherichia coli reveals a role in biofilm formation. J Bacteriol 2008; 190(3): 1054-63.
34. Ong CL, Beatson SA, McEwan AG, Schembri MA. Conjugative plasmid transfer and adhesion dynamics in an Escherichia coli biofilm. Appl Environ Microbiol 2009; 75(21): 6783-91.
35. Ong CL, Beatson SA, Totsika M, Forestier C, McEwan AG, Schembri MA. Molecular analysis of type 3 fimbrial genes from Escherichia coli, Klebsiella and Citrobacter species. BMC Microbiol 2010; 10: 183.
36. Buckles EL, Bahrani-Mougeot FK, Molina A, et al. Identification and characterization of a novel uropathogenic Escherichia coliassociated fimbrial gene cluster. Infect Immun 2004; 72(7): 3890-901.
37. Henderson IR, Cappello R, Nataro JP. Autotransporter proteins, evolution and redefining protein secretion. Trends Microbiol 2000; 8(12): 529-32.
38. Jose J, Jahnig F, Meyer TF. Common structural features of IgA1 protease-like outer membrane protein autotransporters. Mol Microbiol 1995; 18(2): 378-80.
39. Henderson IR, Navarro-Garcia F, Desvaux M, Fernandez RC, Ala'Aldeen D. Type V protein secretion pathway: the autotransporter story. Microbiol Mol Biol Rev 2004; 68(4): 692-744.
40. Allsopp LP, Totsika M, Tree JJ, et al. UpaH is a newly identified autotransporter protein that contributes to biofilm formation and bladder colonization by uropathogenic Escherichia coli CFT073. Infect Immun 2010; 78(4): 1659-69.
41. Parham NJ, Srinivasan U, Desvaux M, Foxman B, Marrs CF, Henderson IR. PicU, a second serine protease autotransporter of uropathogenic Escherichia coli. FEMS Microbiol Lett 2004; 230(1): 73-83.
42. Ulett GC, Valle J, Beloin C, Sherlock O, Ghigo JM, Schembri MA. Functional analysis of antigen 43 in uropathogenic Escherichia coli reveals a role in long-term persistence in the urinary tract. Infect Immun 2007; 75(7): 3233-44.
43. Valle J, Mabbett AN, Ulett GC, et al. UpaG, a new member of the trimeric autotransporter family of adhesins in uropathogenic Escherichia coli. J Bacteriol 2008; 190(12): 4147-61.
44. Totsika M, Wells TJ, Beloin C, et al. Molecular Characterization of the EhaG and UpaG Trimeric Autotransporter Proteins from Pathogenic Escherichia coli. Appl Environ Microbiol 2012; 78(7): 2179-89.
45. Allsopp LP, Beloin C, Ulett GC, et al. Molecular characterization of UpaB and UpaC, two new autotransporter proteins of uropathogenic Escherichia coli CFT073. Infect Immun 2012; 80(1): 321-32.
46. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 2003; 301(5629): 105-7.
47. Ieva R, Bernstein HD. Interaction of an autotransporter passenger domain with BamA during its translocation across the bacterial outer membrane. Proc Natl Acad Sci USA 2009; 106(45): 19120-5.
48. Purdy GE, Fisher CR, Payne SM. IcsA surface presentation in Shigella flexneri requires the periplasmic chaperones DegP, Skp, and SurA. J Bacteriol 2007; 189(15): 5566-73.
49. Ruiz-Perez F, Henderson IR, Leyton DL, Rossiter AE, Zhang Y, Nataro JP. Roles of periplasmic chaperone proteins in the biogenesis of serine protease autotransporters of Enterobacteriaceae. J Bacteriol 2009; 191(21): 6571-83.
50. Ruiz-Perez F, Henderson IR, Nataro JP. Interaction of FkpA, a peptidyl-prolyl cis/trans isomerase with EspP autotransporter protein. Gut Microbes 2010; 1(5): 339-44.
51. Sauri A, Soprova Z, Wickstrom D, et al. The Bam (Omp85) complex is involved in secretion of the autotransporter haemoglobin protease. Microbiology 2009; 155(Pt 12): 3982-91.
52. Wagner JK, Heindl JE, Gray AN, Jain S, Goldberg MB. Contribution of the periplasmic chaperone Skp to efficient presentation of the autotransporter IcsA on the surface of Shigella flexneri. J Bacteriol 2009; 191(3): 815-21.
53. Leyton DL, Rossiter AE, Henderson IR. From self sufficiency to dependence: mechanisms and factors important for autotransporter biogenesis. Nat Rev Microbiol 2012; 10(3): 213-25.
54. Selkrig J, Mosbahi K, Webb CT, et al. Discovery of an archetypal protein transport system in bacterial outer membranes. Nat Struct Mol Biol 2012; 19(5): 506-10.
55. Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 1991; 4(1): 80-128.
56. Wiles TJ, Dhakal BK, Eto DS, Mulvey MA. Inactivation of host Akt/protein kinase B signaling by bacterial pore-forming toxins. Mol Biol Cell 2008; 19(4): 1427-38.
57. Flatau G, Lemichez E, Gauthier M, et al. Toxin-induced activation of the G protein p21 Rho by deamidation of glutamine. Nature 1997; 387(6634): 729-33.
58. Lemonnier M, Landraud L, Lemichez E. Rho GTPase-activating bacterial toxins: from bacterial virulence regulation to eukaryotic cell biology. FEMS Microbiol Rev 2007; 31(5): 515-34.
59. Guyer DM, Radulovic S, Jones FE, Mobley HL. Sat, the secreted autotransporter toxin of uropathogenic Escherichia coli, is a vacuolating cytotoxin for bladder and kidney epithelial cells. Infect Immun 2002; 70(8): 4539-46.
60. Guyer DM, Henderson IR, Nataro JP, Mobley HL. Identification of sat, an autotransporter toxin produced by uropathogenic Escherichia coli. Mol Microbiol 2000; 38(1): 53-66.
61. Parreira VR, Gyles CL. A novel pathogenicity island integrated adjacent to the thrW tRNA gene of avian pathogenic Escherichia coli encodes a vacuolating autotransporter toxin. Infect Immun 2003; 71(9): 5087-96.
62. Nougayrede JP, Homburg S, Taieb F, et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006; 313(5788): 848-51.
63. Chu BC, Garcia-Herrero A, Johanson TH, et al. Siderophore uptake in bacteria and the battle for iron with the host; a bird's eye view. Biometals 2010; 23(4): 601-11.
64. Miethke M, Marahiel MA. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 2007; 71(3): 413-51.
65. Cox GB, Gibson F, Luke RK, Newton NA, O'Brien IG, Rosenberg H. Mutations affecting iron transport in Escherichia coli. J Bacteriol 1970; 104(1): 219-26.
66. Henderson JP, Crowley JR, Pinkner JS, et al. Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli. PLoS Pathog 2009; 5(2): e1000305.
67. Fischbach MA, Lin H, Zhou L, et al. The pathogen-associated iroA gene cluster mediates bacterial evasion of lipocalin 2. Proc Natl Acad Sci USA 2006; 103(44): 16502-7.
68. Bearden SW, Fetherston JD, Perry RD. Genetic organization of the yersiniabactin biosynthetic region and construction of avirulent mutants in Yersinia pestis. Infect Immun 1997; 65(5): 1659-68.
69. Lawlor MS, O'Connor C, Miller VL. Yersiniabactin is a virulence factor for Klebsiella pneumoniae during pulmonary infection. Infect Immun 2007; 75(3): 1463-72.
70. Schubert S, Picard B, Gouriou S, Heesemann J, Denamur E. Yersinia high-pathogenicity island contributes to virulence in Escherichia coli causing extraintestinal infections. Infect Immun 2002; 70(9): 5335-7.
71. Valdebenito M, Crumbliss AL, Winkelmann G, Hantke K. Environmental factors influence the production of enterobactin, salmochelin, aerobactin, and yersiniabactin in Escherichia coli strain Nissle 1917. Int J Med Microbiol 2006; 296(8): 513-20.
72. Bäumler AJ, Norris TL, Lasco T, et al. IroN, a novel outer membrane siderophore receptor characteristic of Salmonella enterica. J Bacteriol 1998; 180(6): 1446-53.
73. Braun V. Iron uptake by Escherichia coli. Front Biosci 2003; 8: S1409-S21.
74. Mabbett AN, Ulett GC, Watts RE, et al. Virulence properties of asymptomatic bacteriuria Escherichia coli. Int J Med Microbiol 2009; 299(1): 53-63.
75. Watts RE, Totsika M, Challinor VL, et al. Contribution of siderophore systems to growth and urinary tract colonization of asymptomatic bacteriuria Escherichia coli. Infect Immun 2012; 80(1): 333-44.
76. Garcia EC, Brumbaugh AR, Mobley HLT. Redundancy and specificity of Escherichia coli iron acquisition systems during urinary tract infection. Infect Immun 2011; 79(3): 1225-35.
77. Rasko DA, Rosovitz MJ, Myers GS, et al. The pangenome structure of Escherichia coli: comparative genomic analysis of E. coli commensal and pathogenic isolates. J Bacteriol 2008; 190(20): 6881-93.
78. Chromek M, Slamova Z, Bergman P, et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med 2006; 12(6): 636-41.
79. Hertting O, Holm A, Luthje P, et al. Vitamin D induction of the human antimicrobial Peptide cathelicidin in the urinary bladder. PLoS One 2010; 5(12): e15580.
80. Vandewalle A. Toll-like receptors and renal bacterial infections. Chang Gung Med J 2008; 31(6): 525-37.
81. Medzhitov R, Janeway CA, Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91(3): 295-8.
82. Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997; 9(1): 4-9.
83. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5(10): 987-95.
84. Svanborg Eden C, Briles D, Hagberg L, McGhee J, Michalec S. Genetic factors in host resistance to urinary tract infection. Infection 1984; 12(2): 118-23.
85. Ashkar AA, Mossman KL, Coombes BK, Gyles CL, Mackenzie R. FimH adhesin of type 1 fimbriae is a potent inducer of innate antimicrobial responses which requires TLR4 and type 1 interferon signalling. PLoS Pathog 2008; 4(12): e1000233.
86. Frendeus B, Wachtler C, Hedlund M, et al. Escherichia coli P fimbriae utilize the Toll-like receptor 4 pathway for cell activation. Mol Microbiol 2001; 40(1): 37-51.
87. Hedges S, Svensson M, Svanborg C. Interleukin-6 response of epithelial cell lines to bacterial stimulation in vitro. Infect Immun 1992; 60(4): 1295-301.
88. Hedlund M, Wachtler C, Johansson E, et al. P fimbriae-dependent, lipopolysaccharide-independent activation of epithelial cytokine responses. Mol Microbiol 1999; 33(4): 693-703.
89. Hedlund M, Frendeus B, Wachtler C, Hang L, Fischer H, Svanborg C. Type 1 fimbriae deliver an LPS-and TLR4-dependent activation signal to CD14-negative cells. Mol Microbiol 2001; 39(3): 542-52.
90. Schilling JD, Mulvey MA, Vincent CD, Lorenz RG, Hultgren SJ. Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism. J Immunol 2001; 166(2): 1148-55.
91. Zhang D, Zhang G, Hayden MS, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004; 303(5663): 1522-6.
92. Andersen-Nissen E, Hawn TR, Smith KD, et al. Cutting edge: Tlr5-/-mice are more susceptible to Escherichia coli urinary tract infection. J Immunol 2007; 178(8): 4717-20.
93. Checroun C, Wehrly TD, Fischer ER, Hayes SF, Celli J. Autophagy-mediated reentry of Francisella tularensis into the endocytic compartment after cytoplasmic replication. Proc Natl Acad Sci USA 2006; 103(39): 14578-83.
94. Cirl C, Wieser A, Yadav M, et al. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. Nat Med 2008; 14(4): 399-406.
95. Martinez JJ, Mulvey MA, Schilling JD, Pinkner JS, Hultgren SJ. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 2000; 19(12): 2803-12.
96. Justice SS, Hunstad DA, Seed PC, Hultgren SJ. Filamentation by Escherichia coli subverts innate defenses during urinary tract infection. Proc Natl Acad Sci USA 2006; 103(52): 19884-9.
97. Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev 2012; 36(3): 616-48.
98. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 2007; 4(12): e329.
99. Bokil NJ, Totsika M, Carey AJ, et al. Intramacrophage survival of uropathogenic Escherichia coli: differences between diverse clinical isolates and between mouse and human macrophages. Immunobiology 2011; 216(11): 1164-71.
100. Baorto DM, Gao Z, Malaviya R, et al. Survival of FimHexpressing enterobacteria in macrophages relies on glycolipid traffic. Nature 1997; 389(6651): 636-9.
101. Deretic V. Autophagy in immunity and cell-autonomous defense against intracellular microbes. Immunol Rev 2011; 240(1): 92-104.
102. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119(6): 753-66.
103. Birmingham CL, Smith AC, Bakowski MA, Yoshimori T, Brumell JH. Autophagy controls Salmonella infection in response to damage to the Salmonella-containing vacuole. J Biol Chem. 2006 Apr 21; 281(16): 11374-83.
104. Gutierrez MG, Vazquez CL, Munafo DB, i. Autophagy induction favours the generation and maturation of the Coxiella-replicative vacuoles. Cell Microbiol 2005; 7(7): 981-93.
105. Romano PS, Gutierrez MG, Beron W, Rabinovitch M, Colombo MI. The autophagic pathway is actively modulated by phase II Coxiella burnetii to efficiently replicate in the host cell. Cell Microbiol 2007; 9(4): 891-909.
106. Kloft N, Neukirch C, Bobkiewicz W, et al. Pro-autophagic signal induction by bacterial pore-forming toxins. Med Microbiol Immunol 2010; 199(4): 299-309.
107. Lievin-Le Moal V, Comenge Y, Ruby V, Amsellem R, Nicolas V, Servin AL. Secreted autotransporter toxin (Sat) triggers autophagy in epithelial cells that relies on cell detachment. Cell Microbiol 2011; 13(7): 992-1013.
108. Amer AO, Byrne BG, Swanson MS. Macrophages rapidly transfer pathogens from lipid raft vacuoles to autophagosomes. Autophagy 2005; 1(1): 53-8.
109. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 2010; 6(8): e1001042.
110. Rogers BA, Aminzadeh Z, Hayashi Y, Paterson DL. Country-tocountry transfer of patients and the risk of multi-resistant bacterial infection. Clin Infect Dis 2011; 53(1): 49-56.
111. Johnson JR, Manges AR, O'Bryan TT, Riley LW. A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Lancet 2002; 359(9325): 2249-51.
112. Manges AR, Johnson JR, Foxman B, O'Bryan TT, Fullerton KE, Riley LW. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med 2001; 345(14): 1007-13.
113. Johnson JR, Murray AC, Kuskowski MA, et al. Distribution and characteristics of Escherichia coli clonal group A. Emerg Infect Dis 2005; 11(1): 141-5.
114. Johnson JR, Menard ME, Lauderdale TL, et al. Global distribution and epidemiologic associations of Escherichia coli clonal group A, 1998-2007. Emerg Infect Dis 2011; 17(11): 2001-9.
115. Coque TM, Novais A, Carattoli A, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum betalactamase CTX-M-15. Emerg Infect Dis 2008; 14(2): 195-200.
116. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61(2): 273-81.
117. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51(3): 286-94.
118. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 2009; 53(7): 2733-9.
119. Karlowsky JA, Hoban DJ, DeCorby MR, Laing NM, Zhanel GG. Fluoroquinolone-Resistant Urinary Isolates of Escherichia coli from Outpatients Are Frequently Multidrug Resistant: Results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study. Antimicrob Agents Chemother 2006; 50(6): 2251-4.
120. Johnson JR, Owens KL, Clabots CR, Weissman SJ, Cannon SB. Phylogenetic relationships among clonal groups of extraintestinal pathogenic Escherichia coli as assessed by multi-locus sequence analysis. Microb Infect 2006; 8(7): 1702-13.
121. Tartof SY, Solberg OD, Manges AR, Riley LW. Analysis of a Uropathogenic Escherichia coli Clonal Group by Multilocus Sequence Typing. J Clin Microbiol 2005; 43(12): 5860-4.
122. Coelho A, Mora A, Mamani R, et al. Spread of Escherichia coli O25b:H4-B2-ST131 producing CTX-M-15 and SHV-12 with high virulence gene content in Barcelona (Spain). J Antimicrob Chemother 2011; 66(3): 517-26.
123. Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol 2008; 46(8): 2605-12.
124. Pitout JD, Gregson DB, Campbell L, Laupland KB. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother 2009; 53(7): 2846-51.
125. Platell JL, Cobbold RN, Johnson JR, Trott DJ. Clonal group distribution of fluoroquinolone-resistant Escherichia coli among humans and companion animals in Australia. J Antimicrob Chemother 2010; 65(9): 1936-8.
126. Sidjabat HE, Derrington P, Nimmo GR, Paterson DL. Escherichia coli ST131 producing CTX-M-15 in Australia. J Antimicrob Chemother 2010; 65(6): 1301-3.
127. Totsika M, Beatson SA, Sarkar S, et al. Insights into a Multidrug Resistant Escherichia coli Pathogen of the Globally Disseminated ST131 Lineage: Genome Analysis and Virulence Mechanisms. PLoS ONE 2011; 6(10): e26578.
128. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53(12): 5046-54.
129. Poirel L, Dortet L, Bernabeu S, Nordmann P. Genetic Features of blaNDM-1-Positive Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55(11): 5403-7.
130. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011; 17(10): 1791-8.
131. Peirano G, Schreckenberger PC, Pitout JDD. Characteristics of NDM-1-Producing Escherichia coli Isolates That Belong to the Successful and Virulent Clone ST131. Antimicrob Agents Chemother 2011; 55(6): 2986-8.
132. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of Metallo-β-Lactamase NDM-1-Producing Multidrug-Resistant Escherichia coli in Australia. Antimicrob Agents Chemother 2010; 54(11): 4914-6.
133. Naas T, Cuzon G, Gaillot O, Courcol R, Nordmann P. When Carbapenem-Hydrolyzing β-Lactamase KPC Meets Escherichia coli ST131 in France. Antimicrob Agents Chemother 2011; 55(10): 4933-4.
134. Nordmann P, Boulanger AE, Poirel L. NDM-4 metallo-ßlactamase with increased carbapenemase activity from Escherichia coli. Antimicrob Agents Chemother 2012; 56(4): 2184-6.
135. Hornsey M, Phee L, Wareham DW. A Novel Variant, NDM-5, of the New Delhi Metallo-β-Lactamase in a Multidrug-Resistant Escherichia coli ST648 Isolate Recovered from a Patient in the United Kingdom. Antimicrob Agents Chemother 2011; 55(12): 5952-4.
136. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2010.
137. Little P, Merriman R, Turner S, et al. Presentation, pattern, and natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection in primary care: observational study. BMJ 2010; 340: b5633.
138. Little P, Moore MV, Turner S, et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ 2010; 340: c199.
139. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52(5): e103-20.
140. Antibiotic Expert Group, Spicer J, Therapeutic Guidelines Limited. Therapeutic guidelines: antibiotic. Version 14. ed. Melbourne, Vic: Therapeutic Guidelines; 2010.
141. Simpson IN, Harper PB, O'Callaghan CH. Principal betalactamases responsible for resistance to beta-lactam antibiotics in urinary tract infections. Antimicrob Agents Chemother 1980; 17(6): 929-36.
142. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66(1): 1-14.
143. Schito GC, Naber KG, Botto H, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34(5): 407-13.
144. Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrumbeta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2010; 54(9): 4006-8.
145. Azap OK, Arslan H, Serefhanoglu K, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010; 16(2): 147-51.
146. Tharavichitkul P, Khantawa B, Bousoung V, Boonchoo M. Activity of Fosfomycin Against Extended-Spectrum-beta-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli in Maharaj Nakorn Chiang Mai Hospital. J Infect Dis Antimicrob Agents 2005; 22(3): 121-6.
147. Oteo J, Orden B, Bautista V, et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 2009; 64(4): 712-7.
148. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. International journal of infectious diseases: IJID: official publication of the Inter Soc Infect Dis 2011; 15(11): e732-9.
149. Ode B, Haidl S, Hoffstedt B, Walder M, Ursing J. Fosfomycin versus ampicillin in the treatment of acute pyelonephritis. Chemioterapia: Inter J Mediterr Soc Chemother 1988; 7(2): 96-100.
150. Pulcini C, Bush K, Craig WA, et al. Forgotten Antibiotics: An Inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 2012; 54(2): 268-74.
151. Rodriguez-Bano J, Alcala JC, Cisneros JM, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168(17): 1897-902.
152. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. beta-Lactam/beta-Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum beta-Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts. Clin Infect Dis 2012; 54(2): 167-74.
153. Pitout JD. Infections with Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae: Changing Epidemiology and Drug Treatment Choices. Drugs 2010; 70(3): 313-33.
154. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18(4): 657-86.
155. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 Suppl 4: S341-5.
156. Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J 2011; 41(6): 441-9.
157. Sidjabat H, Nimmo GR, Walsh TR, et al. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-betalactamase. Clin Infect Dis 2011; 52(4): 481-4.
158. Urban C, Bradford PA, Tuckman M, et al. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin Infect Dis 2008; 46(11): e127-30.
159. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10(9): 597-602.
160. Nix DE, Matthias KR. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother 2010; 65(6): 1311-2.
161. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance Study in Europe and Brazil on Clinical Aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): Implications for Empiric Therapy. European Urology 2008; 54(5): 1164-78.
162. Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006; 27(6): 468-75.
163. Aggen JB, Armstrong ES, Goldblum AA, et al. Synthesis and Spectrum of the Neoglycoside ACHN-490. Antimicrob Agents Chemother 2010; 54(11): 4636-42.
164. Cross AS, Zollinger W, Mandrell R, Gemski P, Sadoff J. Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli. J Infect Dis 1983; 147(1): 68-76.
165. Pluschke G, Achtman M. Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1. Infect Immun 1985; 49(2): 365-70.
166. Uehling DT, Hopkins WJ, Beierle LM, Kryger JV, Heisey DM. Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial. J Infect Dis 2001; 183 Suppl 1: S81-3.
167. O'Hanley P, Lalonde G, Ji G. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis. Infect Immun 1991; 59(3): 1153-61.
168. Langermann S, Palaszynski S, Barnhart M, et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 1997; 276(5312): 607-11.
169. Roberts JA, Kaack MB, Baskin G, et al. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. J Urol 2004; 171(4): 1682-5.
170. Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Olson R, Wilding GE. The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate. Infect Immun 2003; 71(12): 7164-9.
171. Durant L, Metais A, Soulama-Mouze C, Genevard JM, Nassif X, Escaich S. Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli. Infect Immun 2007; 75(4): 1916-25.
172. Scorza FB, Doro F, Rodriguez-Ortega MJ, et al. Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic Escherichia coli DeltatolR IHE3034 mutant. Mol Cell Proteomics 2008; 7(3): 473-85.
173. Wieser A, Romann E, Magistro G, et al. A multi-epitope subunit vaccine conveys protection against extraintestinal pathogenic Escherichia coli in mice. Infect Immun 2010; 78(8): 3432-42.
174. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287(5459): 1816-20.
175. Maione D, Margarit I, Rinaudo CD, et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005; 309(5731): 148-50.
176. Moriel DG, Bertoldi I, Spagnuolo A, et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci USA 2010; 107(20): 9072-7.
177. Old DC. Inhibition of the interaction between fimbrial haemagglutinins and erythrocytes by D-mannose and other carbohydrates. J Gen Microbiol 1972; 71(1): 149-57.
178. Firon N, Ashkenazi S, Mirelman D, Ofek I, Sharon N. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect Immun 1987; 55(2): 472-6.
179. Firon N, Ofek I, Sharon N. Carbohydrate-binding sites of the mannose-specific fimbrial lectins of enterobacteria. Infect Immun 1984; 43(3): 1088-90.
180. Firon N, Ofek I, Sharon N. Carbohydrate specificity of the surface lectins of Escherichia coli, Klebsiella pneumoniae, and Salmonella typhimurium. Carbohydr Res 1983; 120: 235-49.
181. Firon N, Ofek I, Sharon N. Interaction of mannose-containing oligosaccharides with the fimbrial lectin of Escherichia coli. Biochem Biophys Res Commun 1982; 105(4): 1426-32.
182. Neeser JR, Koellreutter B, Wuersch P. Oligomannoside-type glycopeptides inhibiting adhesion of Escherichia coli strains mediated by type 1 pili: preparation of potent inhibitors from plant glycoproteins. Infect Immun 1986; 52(2): 428-36.
183. Lindhorst TK, Kieburg C, Krallmann-Wenzel U. Inhibition of the type 1 fimbriae-mediated adhesion of Escherichia coli to erythrocytes by multiantennary alpha-mannosyl clusters: the effect of multivalency. Glycoconj J 1998; 15(6): 605-13.
184. Nagahori N, Lee RT, Nishimura S, Page D, Roy R, Lee YC. Inhibition of adhesion of type 1 fimbriated Escherichia coli to highly mannosylated ligands. Chembiochem 2002; 3(9): 836-44.
185. Bouckaert J, Berglund J, Schembri M, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol 2005; 55(2): 441-55.
186. Han Z, Pinkner JS, Ford B, et al. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 2010; 53(12): 4779-92.
187. Cusumano CK, Pinkner JS, Han Z, et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med 2011; 3(109): 109ra15.
188. Pinkner JS, Remaut H, Buelens F, et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci USA 2006; 103(47): 17897-902.
189. Nishiyama M, Horst R, Eidam O, et al. Structural basis of chaperone-subunit complex recognition by the type 1 pilus assembly platform FimD. EMBO J 2005; 24(12): 2075-86.
190. Cegelski L, Pinkner JS, Hammer ND, et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. Nat Chem Biol 2009; 5(12): 913-9.
191. Chorell E, Bengtsson C, Sainte-Luce Banchelin T, et al. Synthesis and application of a bromomethyl substituted scaffold to be used for efficient optimization of anti-virulence activity. Eur J Med Chem 2011; 46(4): 1103-16.
192. Andersson P, Engberg I, Lidin-Janson G, et al. Persistence of Escherichia coli bacteriuria is not determined by bacterial adherence. Infect Immun 1991; 59(9): 2915-21.
193. Hull R, Rudy D, Donovan W, et al. Urinary tract infection prophylaxis using Escherichia coli 83972 in spinal cord injured patients. J Urol 2000; 163(3): 872-7.
194. Lindberg U, Hanson LA, Jodal U, Lidin-Janson G, Lincoln K, Olling S. Asymptomatic bacteriuria in schoolgirls. II. Differences in Escherichia coli causing asymptomatic and symptomatic bacteriuria. Acta Paediatr Scand 1975; 64(3): 432-6.
195. Sundén F, Håkansson L, Ljunggren E, Wullt B. Bacterial interference-is deliberate colonization with Escherichia coli 83972 an alternative treatment for patients with recurrent urinary tract infection? Int J Antimicrob Agents 2006; 28: S26-S9.
196. Wullt B, Connell H, Röllano P, Månsson W, Colleen S, Svanborg C. Urodynamic factors influence the duration of Escherichia coli bacteriuria in deliberately colonized cases. J Urol 1998; 159(6): 2057-62.
197. Darouiche RO, Donovan WH, Del Terzo M, Thornby JI, Rudy DC, Hull RA. Pilot trial of bacterial interference for preventing urinary tract infection. Urology 2001; 58(3): 339-44.
198. Darouiche RO, Thornby JI, Cerra-Stewart C, Donovan WH, Hull RA. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. Clin Infect Dis 2005; 41(10): 1531-4.
199. Trautner BW, Hull RA, Darouiche RO. Escherichia coli 83972 inhibits catheter adherence by a broad spectrum of uropathogens. Urology 2003; 61(5): 1059-62.
200. Klemm P, Roos V, Ulett GC, Svanborg C, Schembri MA. Molecular characterization of the Escherichia coli asymptomatic bacteriuria strain 83972: the taming of a pathogen. Infect Immun 2006; 74(1): 781-5.
201. Roos V, Nielsen EM, Klemm P. Asymptomatic bacteriuria Escherichia coli strains: adhesins, growth and competition. FEMS Microbiol Lett 2006; 262(1): 22-30.
202. Roos V, Schembri MA, Ulett GC, Klemm P. Asymptomatic bacteriuria Escherichia coli strain 83972 carries mutations in the foc locus and is unable to express F1C fimbriae. Microbiology 2006; 152: 1799-806.
203. Wullt B, Bergsten G, Connell H, et al. P-fimbriae trigger mucosal responses to Escherichia coli in the human urinary tract. Cell Microbiol 2001; 3(4): 255-64.
204. Trautner BW, Darouiche RO, Hull RA, Hull S, Thornby JI. Preinoculation of urinary catheters with Escherichia coli 83972 inhibits catheter colonization by Enterococcus faecalis. J Urol 2002; 167(1): 375-9.
205. Klemm P, Hancock V, Schembri MA. Mellowing out: adaptation to commensalism by Escherichia coli asymptomatic bacteriuria strain 83972. Infect Immun 2007; 75(8): 3688-95.
206. Roos V, Ulett GC, Schembri MA, Klemm P. The asymptomatic bacteriuria Escherichia coli strain 83972 outcompetes uropathogenic E. coli strains in human urine. Infect Immun 2006; 74(1): 615-24.
207. Mabbett AN, Ulett GC, Watts RE, et al. Virulence properties of asymptomatic bacteriuria Escherichia coli. Int J Med Microbiol 2009; 299(1): 53-63.
208. Sundén F, Håkansson L, Ljunggren E, Wullt B. Escherichia coil 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol 2010; 184(1): 179-85.
209. Trautner BW, Lopez AI, Kumar A, et al. Nanoscale surface modification favors benign biofilm formation and impedes adherence by pathogens. Nanomedicine 2011; 8(3): 261-70.